Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell and multi-omics data. We have a diverse and multi-disciplinary team, supported by world-leading scientific advisors and reputable investors.

Products, services, technology

Scailyte provides a rapid and efficient end-to-end pipeline for extracting relevant biosignatures from single-cell and multi-omics data related to efficacy, toxicity or to the mode of action of therapeutics.

Cooperation possibilities

We are partnering with biotech companies in the field of immuno-oncology that are entering Phase 1 clinical trials and want to leverage our unique capabilities in biomarker discovery and patient stratification. Reach our if you want to learn more:

Facts & figures
  • Type of organization
    Private company
  • Year of foundation
  • Number of employees in Switzerland

You may also be interested in